Erythropoietin-mediated decrease of the redox-sensitive transcription factor NF-kappaB is inversely correlated with...

Area of Science:

• Nephrology and Immunology
• Molecular Biology and Genetics

Background:

• Anemia is common in end-stage renal failure (ESRF) patients undergoing hemodialysis.
• Recombinant human erythropoietin (rh-EPO) is used to treat anemia.
• The transcription factor NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells) is involved in inflammatory responses.

Purpose of the Study:

• To investigate the in vivo and in vitro effects of rh-EPO on the redox-sensitive transcription factor NF-kappaB in ESRF patients.
• To explore the relationship between rh-EPO treatment, hemoglobin levels, and NF-kappaB activity.

Main Methods:

• Electrophoretic mobility shift assays (EMSA) were used to measure NF-kappaB binding activity in mononuclear cells from ESRF patients before and during rh-EPO therapy.
• Patients were categorized into 'good' and 'poor' responders to rh-EPO.
• In vitro studies involved THP-1 cells, rh-EPO, and erythrocytes with varying hemoglobin levels.

Main Results:

• In 'good responders,' rh-EPO initially reduced NF-kappaB activity and increased hemoglobin, but the effect on NF-kappaB diminished over time.
• 'Poor responders' showed increased NF-kappaB activity with only a moderate rise in hemoglobin.
• In vitro, rh-EPO did not directly affect NF-kappaB, but co-incubation with erythrocytes at normal hemoglobin levels (11 g/dl) reduced NF-kappaB activity compared to anemia levels (8 g/dl).

Conclusions:

• rh-EPO's effect on NF-kappaB is complex and may be influenced by hemoglobin levels and erythrocyte interactions.
• The initial reduction in NF-kappaB activity by rh-EPO in anemia patients is transient.
• Further research is needed to elucidate the intricate interplay between rh-EPO, red blood cells, and NF-kappaB signaling.